Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients
Daobin Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiangyang Zhang, Zimin Sun(University of Science and Technology of China), Shuhua Yi(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Xu(Jiangsu Province Hospital), Zunmin Zhu(Zhengzhou University), Renbin Zhao(Kunming University of Science and Technology), Zhengzheng Fu(Soochow University), Wei Zhao, Jianda Hu(Fujian Medical University), Dengju Li(Tongji Hospital), Huaqiang Zhu(Zhejiang Pharmaceutical College), Yongping Song(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Bin Zhang(Ningbo University), Ting Liu(Chinese PLA General Hospital), Wei Yang(China Medical University), Yamin Tian, Jie Jin(Beijing Institute of Technology), Guohui Cui(Union Hospital), Bing Xu(First Affiliated Hospital of Xiamen University)
Cited by 11
Related Papers
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
|EBioMedicine|2016|345
Targeting CD47 for cancer immunotherapy
|Journal of Hematology & Oncology|2021|342
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256